Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Sonia Glennie"'
Autor:
Neil Bailey, Tori Braun, Megumi Bailey, Tenzin Tsomo, Jennie Szeto, Sandra Benitez Kruidenier, Vanessa Dunleavy, Joanna Fesler, Gayle Funk, Sonia Glennie, Judson Hall, Julia Parker, Daniel Egan, Raya Mawad, Carol A Dean, Suzan Sullivan, Chia Lu, Heidi Hohmann, Jordan Briggs, Krish Patel
Publikováno v:
Blood. 140:3765-3766
Autor:
Krish Patel, Megumi Bailey, Neil Bailey, Suzanne Fanning, Kayla Gulley, Jens Frisvold, Sonia Glennie, Vanessa Dunleavy, Sandra Benitez-Kruidenier, Julia Parker, Shannon Williams, Suzan Sullivan, Carol Dean, Heidi Hohmann, Chiachun Lu, Catherine Tierney, Grace Mun, Daniel Nathan Egan, James Essell
Publikováno v:
Transplantation and Cellular Therapy. 29:S207
Autor:
Megumi Bailey, Tenzin Tsomo, Neil Bailey, Tori Braun, Chiachun Lu, Carol Dean, Shannon Williams, Gayle Funk, Joanna Fesler, Sonia Glennie, Judson Hall, Vanessa Dunleavy, Daniel Egan, Raya Mawad, Livia Hegerova, Krish Patel, John M. Pagel, William Bensinger
Publikováno v:
Transplantation and Cellular Therapy. 28:S239-S240
Autor:
Tori Braun, Vanessa Dunleavy, Gayle Funk, Megumi Bailey, Neil Bailey, Krish Patel, Livia Hegerova, Tenzin Tsomo, Heidi Hohmann, Judson Hall, John M. Pagel, Sonia Glennie, Jordan Briggs, William I. Bensinger, Jennie Szeto, Daniel J. Egan, Raya Mawad, Joanna Fesler, Joshua Mark
Publikováno v:
Blood. 138:4554-4554
Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) often have a poor prognosis despite therapies using second-line chemoimmunotherapy (CIT). Achievement of complete response (CR) with second-line therapy is asso
Autor:
Raya Mawad, Krish Patel, John M. Pagel, Livia Hegerova, Sonia Glennie, Joseph F. Ferry, Vanessa Dunleavy, Judson Hall, Neil Bailey, Joanna Fesler, Daniel J. Egan, William I. Bensinger
Publikováno v:
Blood. 136:13-14
Background : Central line associated blood stream infections (CLABSI) have been the costliest of all healthcare associated infections. The average CLABSI cost is approximately $46,000 (Haddadin & Regunath, 2019). Most cases may be preventable with ut
Autor:
Neil Bailey, Tenzin Tsomo, Livia Hegerova, David Kane, Sonia Glennie, William I. Bensinger, Raya Mawad, Ami Batchelder, Joey Ferry, John M. Pagel, Heather Holdread, Jennie Szeto, Daniel J. Egan, Krish Patel, Judson Hall, Joanna Fesler, Megumi Bailey
Publikováno v:
Blood. 136:34-34
Background: Patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) often have a poor prognosis despite therapies using second-line chemoimmunotherapy. Achievement of CR with second-line therapy is associated with improved long-